Search - tctmd.com

Displaying 981 - 1000 of 1013

Sort: Relevancy | Date

News Daily News

RE-VERSE AD：中期分析表明达比加群中和剂似乎安全有效

June 25, 2015

News Daily News

ACCOAST Analysis Identifies Factors Tied to Higher Bleeding Risks in NSTE-ACS

Todd Neale

June 22, 2015

News Industry News

Neuravi Announces €19M ($21M) in Financing to Advance Innovative Minimally Invasive Stroke Therapy

June 17, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

June 05, 2015

News Industry News

Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treat

May 26, 2015

News Daily News

Long-term Ticagrelor Therapy Cost-Effective in US Patients

L.A. McKeown

February 02, 2015

News Daily News

Unless Chronic, Operator Sleep Deprivation Not Tied to Unsafe PCI

January 28, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Todd Neale

January 28, 2015

News Daily News

Link Between PCI Volume and Outcomes Remains Intact

Todd Neale

September 13, 2014

News Daily News

Hybrid Revascularization Still Not Widely Available in US Hospitals Even With Proven Efficacy, Safety

L.A. McKeown

August 07, 2014

News Features

Advocacy Group Blasts Mobile Cardiovascular Screening Company for ‘Unethical’ Practices

Yael L. Maxwell

June 27, 2014

News Daily News

与华法林或阿司匹林相比，阿哌沙班更具成本效益

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban es Rentable comparado con Warfarina o Aspirina

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Caitlin E. Cox

February 26, 2014

Presentation

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Presenter: Paul Dorian

February 20, 2014

News Daily News

Una Escala del Riesgo Predice la Mortalidad a Largo Plazo tras PCI

Caitlin E. Cox

February 03, 2014

News Daily News

Risk Score Predicts Long-term Mortality After PCI

Caitlin E. Cox

February 03, 2014

News Daily News

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

July 25, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

Advertisement

RE-VERSE AD：中期分析表明达比加群中和剂似乎安全有效

ACCOAST Analysis Identifies Factors Tied to Higher Bleeding Risks in NSTE-ACS

Neuravi Announces €19M ($21M) in Financing to Advance Innovative Minimally Invasive Stroke Therapy

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treat

Long-term Ticagrelor Therapy Cost-Effective in US Patients

Unless Chronic, Operator Sleep Deprivation Not Tied to Unsafe PCI

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Link Between PCI Volume and Outcomes Remains Intact

Hybrid Revascularization Still Not Widely Available in US Hospitals Even With Proven Efficacy, Safety

Advocacy Group Blasts Mobile Cardiovascular Screening Company for ‘Unethical’ Practices

与华法林或阿司匹林相比，阿哌沙班更具成本效益

Apixaban es Rentable comparado con Warfarina o Aspirina

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Una Escala del Riesgo Predice la Mortalidad a Largo Plazo tras PCI

Risk Score Predicts Long-term Mortality After PCI

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content